The Outcomes of Intracavernosal Umbilical Cord Mesenchymal Stem Cells Implantation in Patients With Diabetic Erectile Dysfunction

Urologic Diseases Clinical Trial

Official title:

The Outcomes of Intracavernosal Umbilical Cord Mesenchymal Stem Cells Implantation in Patients With Diabetic Erectile Dysfunction

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04972890
• Other study ID #: 19-04-0516
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: October 27, 2020
• Est. completion date: January 31, 2023

Study information

• Verified date: March 2022
• Source: Indonesia University
• Contact: Gampo A Irdam
• Phone: +6281318612618
• Email: gampoai[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Erectile dysfunction (ED) is a complex condition affecting men worldwide. Diabetes mellitus (DM) is one of the most common causes of ED. The prevalence of ED in DM varies around 35-85%. Recently, stem cell therapy has started to become the focus of experimental and clinical studies for the treatment of ED. Stem cells have been shown to be able to regenerate functionally damaged tissue, depending on the stimuli or signals received. Stem cells studies in experimental animals have been carried out using biomarker parameters, including VEGF, Bcl-2, E-selectin, cGMP, eNOS and have been shown to be successful in increasing cell survival and angiogenesis, stimulating antiapoptotic, proneurogenic, proinflammatory, and antifibrotic effects and improvements to these biomarker parameters. This study aims to determine the efficacy, mechanism of action, and safety of umbilical cord mesenchymal stem cells as a therapy for ED due to type 2 diabetes in human.

Description:

Prior to conducting clinical trials, researchers asked for written informed consent. If the subject agrees, the study will direct the subject and control to collect basic data in the form of vital signs, blood pressure, filling out the IIEF-5 questionnaire, complete blood count (CBC), lipid profile, fasting blood glucose, HbA1c, and total testosterone, biomarker examination (E-Selectin), VEGF, Bcl-2, miRNA 16, miRNA 126), and penile Doppler ultrasound. The diagnosis of erectile dysfunction was made on the basis of an IIEF-5 score <22. Penile Doppler ultrasound was performed by a senior radiologist with interpretation of the ultrasound images performed and reported in a blinded fashion (the reader/interpreter does not know the patient's complaints). Penile Doppler ultrasound examination was performed under flaccid conditions and post-sexual stimulation conditions. Prior to the examination, the patient was given sildenafil 100 mg orally, then the flaccid phase was examined. Patients were asked to perform sexual stimulation of themselves and measurements were taken afterwards. Parallel with the patient recruitment, stem cells processing was carried out based on the production method using xeno-free material. At the baseline, patient receive intracavernous injection procedure, as a following steps: - The base of the penis is clamped with ethiloop before the injection is performed. - Intracavernous injection was performed in each body of 7.5 x 10^6 cells/1cc. - Clamps are removed after 30 minutes post-injection to increase stem cell residency and grafting time. After the procedure, we monitor the symptoms for 1 hour to assess the presence or absence of complications before the subject can go home. We also administer PDE-5 inhibitor to all research subjects, namely tadalafil at a dose of 1 x 2.5 mg for 3 months. Follow-up was carried out on all subjects both from the experimental group and the control group by evaluating parameters consisting of IIEF-5, DPL, Lipid profile, HbA1c, GDS, total testosterone, Doppler ultrasound, e-selectin, Bcl-2, VEGF, miRNA 16, miRNA 126 at first and third month after baseline. After all data have been collected, we will perform data analysis and make research report.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: January 31, 2023
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Age 18-65 years old
• willing to participate as research subject
• patient with erectile dysfunction and Diabetes Mellitus type 2 with IIEF-5 score <22
• patient has sexual partner and sexually active
• patient is currently not consuming PDE-5 inhibitor drugs

Exclusion Criteria:

• patient has psychopathology and/or mental retardation
• patient with Peyronie's disease
• patient with hypogonadism
• patient has malignancy in urological and non urological fields
• patient has history of cardiovascular disease with intermediate and high risk

Related Conditions & MeSH terms

• Erectile Dysfunction
• Erectile Dysfunction With Diabetes Mellitus
• Urologic Diseases

Intervention

Biological:
• stem cells
Using umbilical cord stem cells 15x10^6 cells in 2 cc saline/NaCl 0,9% solution

Other:
• placebo
using 2 cc saline/NaCl 0,9% solution

Locations

Country	Name	City	State
Indonesia	Universitas Indonesia	Jakarta Pusat	DKI Jakarta

Sponsors (1)

Lead Sponsor	Collaborator
Indonesia University

Country where clinical trial is conducted

Indonesia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in IIEF-5 Score after stem cells injection	using IIEF-5 Questionnaire [numeric scale from 0 to 25] higher IIEF-5 Score means better erectile function	The questionnaire will be completed at baseline, 1st month, and 3rd month
Primary	Changes in Peak Systolic Velocity (PSV) after stem cells injection	evaluated by penile doppler ultrasound [ numeric scale in cm/s] The normal value is 35cm/s, PSV <35cm/s means worse erectile function	The evaluation will be completed at baseline, 1st month, and 3rd month
Primary	Changes in End Diastolic Velocity after stem cells injection	evaluated by penile doppler ultrasound [ numeric scale in cm/s] The normal value is 5 cm/s, EDV >5cm/s means worse erectile function	The evaluation will be completed at baseline, 1st month, and 3rd month
Primary	Changes in Resistive Index after stem cells injection	evaluated by penile doppler ultrasound [numeric scale] The normal value is >0.9, if RI<0.75 means worse erectile function	The evaluation will be completed at baseline, 1st month, and 3rd month
Primary	Changes in Pulsatility Index after stem cells injection	evaluated by penile doppler ultrasound [numeric scale]	The evaluation will be completed at baseline, 1st month, and 3rd month
Primary	Changes in E-selectin expression after stem cells injection	evaluated by biomolecular examination using blood sample [numeric scale]	The evaluation will be completed at baseline, 1st month, and 3rd month
Primary	Changes in Vascular Endothelial Growth Factor (VEGF) expression after stem cells injection	evaluated by biomolecular examination using blood sample [numeric scale]	The evaluation will be completed at baseline, 1st month, and 3rd month
Primary	Changes in Bcl-2 expression after stem cells injection	evaluated by biomolecular examination using blood sample [numeric scale]	The evaluation will be completed at baseline, 1st month, and 3rd month
Primary	Changes in microRNA 16 expression after stem cells injection	evaluated by biomolecular examination using blood sample [numeric scale]	The evaluation will be completed at baseline, 1st month, and 3rd month
Primary	Changes in microRNA 126 expression after stem cells injection	evaluated by biomolecular examination using blood sample [numeric scale]	The evaluation will be completed at baseline, 1st month, and 3rd month
Secondary	Changes in Hba1c after stem cells injection	using blood sample [numeric scale in %]	The evaluation will be completed at baseline and 3rd month
Secondary	Changes in Fasting Blood Glucose after stem cells injection	using blood sample [numeric scale in mg/dL]	The evaluation will be completed at baseline and 3rd month
Secondary	Changes in total cholesterol after stem cells injection	using blood sample [numeric scale in mg/dL]	The evaluation will be completed at baseline, 1st month, and 3rd month
Secondary	Changes in low-density lipoprotein (LDL) after stem cells injection	using blood sample [numeric scale in mg/dL]	The evaluation will be completed at baseline, 1st month, and 3rd month
Secondary	Changes in high-density lipoprotein (HDL) after stem cells injection	using blood sample [numeric scale in mg/dL]	The evaluation will be completed at baseline, 1st month, and 3rd month
Secondary	Changes in Triglycerides (TG) level after stem cells injection	using blood sample [numeric scale in mg/dL]	The evaluation will be completed at baseline, 1st month, and 3rd month
Secondary	Number of participants with side effects after intracavernosal injection	To evaluate the number of participants with side effects including: pain, swelling, bleeding, hypesthesia, and voiding difficulty after the injection.	The evaluation will be completed at baseline after the injection